Lip Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LPC002 MIFTS: 47	Lip Cancer Categories: Cancer diseases, Eye diseases, Gastrointestinal diseases, Oral diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Lip Cancer

MalaCards integrated aliases for Lip Cancer:

Name: Lip Cancer ¹² ¹⁵

Lip Neoplasms ⁴⁴ ⁷³

Malignant Neoplasm of Oral Aspect of Lip, Not Specified Whether Upper or Lower ¹²

Malignant Neoplasm of External Lip, Not Specified As Upper or Lower ¹²

Malignant Neoplasm of Labial Commissure of Lip ¹²

Malignant Neoplasm of Lower Lip, Buccal Aspect ¹²

Malignant Neoplasm of Lower Lip, Inner Aspect ¹²

Malignant Neoplasm of Vermilion Border of Lip ¹²

Malignant Neoplasm of Lower Lip, Oral Aspect ¹²

Malignant Neoplasm of Lip, Vermilion Border ¹²

Malignant Neoplasm of Other Sites of Lip ¹²

Malignant Neoplasm of Commissure of Lip ¹²

Malignant Neoplasm of Lip, Inner Aspect ¹²

Malignant Neoplasm of Lower Lip, Mucosa ¹²

Malignant Tumor of Lower Labial Mucosa ¹²

Malignant Tumour of Labial Commissure ¹²

Malignant Tumor of Commissure of Lip ¹²

Malignant Neoplasm of Lip, External ¹²

Malignant Tumor of Labial Mucosa ¹²

Malignant Tumor of the Lip ¹²

Malignant Neoplasm of Lip ¹²

Malignant Tumour of Lip ¹²

Malignant Tumor of Lip ¹²

Cancer of Lip ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases Eye diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of lip, oral cavity and pharynx

Malignant neoplasm of lip

Malignant neoplasm: Commissure of lip

Malignant neoplasm: Lip, unspecified

Malignant neoplasm: Lip, unspecified, inner aspect

Malignant neoplasm: Lower lip, inner aspect

External Ids:

Disease Ontology ¹² DOID:8564

ICD10 ³³ C00 C00.9 C00.4 more

ICD9CM ³⁵ 140 140.6 140.8

MeSH ⁴⁴ D008048

NCIt ⁵⁰ C7485

SNOMED-CT ⁶⁸ 93762003 93869001

UMLS ⁷³ C0153340 C0153346 C0153347 more

Sources

Summaries for Lip Cancer

MalaCards based summary : Lip Cancer, also known as lip neoplasms, is related to tongue cancer and cheilitis. An important gene associated with Lip Cancer is SUMO1 (Small Ubiquitin-Like Modifier 1), and among its related pathways/superpathways are Gene Expression and Cell Cycle, Mitotic. The drugs Cobalt and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and brain, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and craniofacial

Sources

Related Diseases for Lip Cancer

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm	Lip Carcinoma in Situ
in Situ Carcinoma	Eye Carcinoma in Situ

Diseases related to Lip Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)

#	Related Disease	Score	Top Affiliating Genes
1	tongue cancer	30.7	CDKN1A TP53
2	cheilitis	29.5	MDM2 MSH2 SUMO1 TP53
3	actinic cheilitis	29.3	CDKN1A MDM2 MSH2 TP53
4	lower lip cancer	12.2
5	upper lip cancer	12.2
6	oral cancer	10.9
7	nasopharyngeal carcinoma	10.7
8	oropharynx cancer	10.5
9	oral cavity cancer	10.5
10	malignant epithelial tumor of salivary glands	10.5
11	hypopharynx cancer	10.4
12	gum cancer	10.3
13	tonsil cancer	10.3
14	salivary gland carcinoma	10.2
15	epiglottis neoplasm	10.2
16	vallecula cancer	10.2
17	soft palate cancer	10.2
18	upper gum cancer	10.2
19	uvula cancer	10.2
20	postcricoid region cancer	10.2
21	aryepiglottic fold cancer	10.2
22	tonsillar pillar cancer	10.2
23	cheek mucosa cancer	10.2
24	sublingual gland cancer	10.2
25	retromolar area cancer	10.2
26	waldeyer's ring cancer	10.2
27	tonsillar fossa cancer	10.2
28	parotid gland cancer	10.2
29	lower gum cancer	10.2
30	hard palate cancer	10.2
31	submandibular gland cancer	10.2
32	vestibule of mouth cancer	10.2
33	pyriform sinus cancer	10.2
34	cerebral primitive neuroectodermal tumor	10.1	MSH2 TP53
35	intestinal benign neoplasm	10.1	MSH2 TP53
36	ring chromosome 7	10.1	MDM2 TP53
37	zika virus infection	10.1	MDM2 TP53
38	familial colorectal cancer	10.1	MSH2 TP53
39	sclerosing liposarcoma	10.1	MDM2 TP53
40	liposarcoma	10.1	MDM2 TP53
41	uterine anomalies	10.1	MSH2 TP53
42	periosteal osteogenic sarcoma	10.1	MDM2 TP53
43	colorectal adenoma	10.1	MSH2 TP53
44	gliomatosis cerebri	10.1	MDM2 TP53
45	soft tissue sarcoma	10.1	MDM2 TP53
46	dedifferentiated liposarcoma	10.1	MDM2 TP53
47	small cell sarcoma	10.1	MDM2 TP53
48	myxosarcoma	10.1	MDM2 TP53
49	verrucous carcinoma	10.1	MDM2 TP53
50	embryonal sarcoma	10.1	MDM2 TP53

Graphical network of the top 20 diseases related to Lip Cancer:

Sources

Symptoms & Phenotypes for Lip Cancer

GenomeRNAi Phenotypes related to Lip Cancer according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.02	CDKN1A MDM2 MSH2 SUMO1 TP53

MGI Mouse Phenotypes related to Lip Cancer:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	craniofacial	MP:0005382	9.46	CDKN1A MDM2 SUMO1 TP53
2	digestive/alimentary	MP:0005381	9.35	CDKN1A MDM2 MSH2 SUMO1 TP53
3	neoplasm	MP:0002006	8.92	CDKN1A MDM2 MSH2 TP53

Sources

Drugs & Therapeutics for Lip Cancer

Drugs for Lip Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 278)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cobalt

Approved, Experimental

Phase 3

7440-48-4

104729

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1

51-21-8

3385

Aldesleukin

Approved

Phase 3,Phase 2,Not Applicable

85898-30-2, 110942-02-4

Tegafur

Approved, Investigational

Phase 3,Phase 2

17902-23-7

5386

Epinephrine

Approved, Vet_approved

Phase 3,Phase 2

51-43-4

5816

Epirubicin

Approved

Phase 3,Phase 2,Phase 1

56420-45-2

41867

Racepinephrine

Approved

Phase 3,Phase 2

329-65-7

838

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 1,Phase 2

33069-62-4

36314

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Histamine

Approved, Investigational

Phase 3

51-45-6, 75614-87-8

774

Doxepin

Approved, Investigational

Phase 3

1668-19-5

667477 667468

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Fluconazole

Approved, Investigational

Phase 2, Phase 3

86386-73-4

3365

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Cevimeline

Approved

Phase 3

107233-08-9

83898 25137844

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 3

595-33-5

11683

Vincristine

Approved, Investigational

Phase 3

57-22-7, 2068-78-2

5978

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

leucovorin

Approved

Phase 3,Phase 2,Phase 1

58-05-9

6006 143

Methotrexate

Approved

Phase 3,Phase 2

59-05-2, 1959-05-2

126941

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2

68538-85-2

Cetuximab

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

205923-56-4

56842117 2333

Isotretinoin

Approved

Phase 3,Phase 2

4759-48-2

5538 5282379

Tocopherol

Approved, Investigational

Phase 3

1406-66-2

14986

Lenograstim

Approved, Investigational

Phase 3,Phase 2,Phase 1

135968-09-1

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1

59-30-3

6037

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 3

59-02-9

14985

Pancreatic Polypeptide

Investigational

Phase 3

59763-91-6

Porfiromycin

Investigational

Phase 3

801-52-5

Tocotrienol

Investigational

Phase 3

6829-55-6

Antimetabolites

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Anti-HIV Agents

Phase 3,Phase 2,Not Applicable

Anti-Infective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Interleukin-2

Phase 3,Phase 2

Anti-Retroviral Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antiviral Agents

Phase 3,Phase 1,Phase 2,Not Applicable

s 1 (combination)

Phase 3,Phase 2

Sympathomimetics

Phase 3,Phase 2

Peripheral Nervous System Agents

Phase 3,Phase 1,Phase 2,Not Applicable

Vasoconstrictor Agents

Phase 3,Phase 2

Autonomic Agents

Phase 3,Phase 2,Not Applicable

Epinephryl borate

Phase 3,Phase 2

Mydriatics

Phase 3,Phase 2

Adrenergic beta-Agonists

Phase 3,Phase 2

Neurotransmitter Agents

Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 295)

#	Name	Status	NCT ID	Phase	Drugs
1	Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip	Completed	NCT00868088	Phase 4
2	Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer	Unknown status	NCT00002747	Phase 3	cisplatin;fluorouracil
3	Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx	Unknown status	NCT00002702	Phase 3
4	PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer	Unknown status	NCT00720070	Phase 3
5	S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer	Unknown status	NCT00336947	Phase 3	tegafur-gimeracil-oteracil potassium;tegafur-uracil
6	Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer	Unknown status	NCT00002659	Phase 3	cisplatin-e therapeutic implant
7	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	Completed	NCT01156142	Phase 3	doxepin hydrochloride
8	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
9	Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	Completed	NCT00090337	Phase 3
10	Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00002533	Phase 2, Phase 3	fluconazole
11	Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	Completed	NCT00017511	Phase 3	cevimeline hydrochloride
12	Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer	Completed	NCT00006799	Phase 3	megestrol acetate
13	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002507	Phase 3	mitomycin C;porfiromycin
14	Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx	Completed	NCT00004234	Phase 3
15	Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer	Completed	NCT00004917	Phase 3	cisplatin
16	Radiation Therapy in Treating Patients With Head and Neck Cancer	Completed	NCT00021125	Phase 3
17	Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002888	Phase 3	cisplatin;fluorouracil;paclitaxel
18	Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery	Completed	NCT00002670	Phase 3	chemotherapy;cisplatin
19	Phase II Trial of Allovectin-7® for Head and Neck Cancer	Completed	NCT00050388	Phase 3
20	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002476	Phase 3	fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
21	Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	Completed	NCT00003809	Phase 3	cisplatin
22	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00771641	Phase 3
23	Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer	Completed	NCT00003328	Phase 3	porfiromycin
24	Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00002654	Phase 3	chemotherapy;cisplatin
25	High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer	Completed	NCT00002555	Phase 3	cisplatin
26	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00003888	Phase 3	cisplatin;docetaxel;fluorouracil
27	Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer	Completed	NCT00006481	Phase 3	Biafine cream
28	Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer	Completed	NCT00054561	Phase 3	isotretinoin
29	Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery	Completed	NCT00003576	Phase 3	cisplatin;fluorouracil
30	Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer	Completed	NCT00608205	Phase 3	cisplatin;fluorouracil
31	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	Completed	NCT00095875	Phase 3	carboplatin;cisplatin;docetaxel;fluorouracil
32	Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00003592	Phase 3	methotrexate;paclitaxel
33	Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer	Completed	NCT00820248	Phase 3	cisplatin
34	Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer	Active, not recruiting	NCT01810913	Phase 2, Phase 3	cisplatin;docetaxel
35	Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer	Active, not recruiting	NCT00956007	Phase 3
36	Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer	Active, not recruiting	NCT00047008	Phase 3	cisplatin
37	Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer	Terminated	NCT00017277	Phase 3
38	S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat	Terminated	NCT00006994	Phase 3	l-glutamine placebo
39	Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer	Terminated	NCT00360971	Phase 3	cisplatin
40	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery	Terminated	NCT00113399	Phase 3	cisplatin;docetaxel;fluorouracil;paclitaxel
41	Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	Withdrawn	NCT00041171	Phase 3	Hypericum perforatum;docetaxel
42	CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy	Withdrawn	NCT01545687	Phase 3
43	Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence	Withdrawn	NCT01142414	Phase 3	cisplatin;fluorouracil
44	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer	Unknown status	NCT00006051	Phase 2	cisplatin;fluorouracil
45	Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery	Unknown status	NCT00357617	Phase 1, Phase 2	celecoxib
46	Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer	Unknown status	NCT00003251	Phase 1, Phase 2	amifostine trihydrate;cisplatin;paclitaxel
47	Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck	Unknown status	NCT00003182	Phase 1, Phase 2	cisplatin;gemcitabine hydrochloride
48	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx	Unknown status	NCT00004094	Phase 2	carboplatin;fluorouracil;hydroxyurea;paclitaxel
49	Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer	Unknown status	NCT00566540	Phase 2	Cisplatin;Paclitaxel
50	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir

Search NIH Clinical Center for Lip Cancer

Cochrane evidence based reviews: lip neoplasms

Sources

Genetic Tests for Lip Cancer

Sources

Anatomical Context for Lip Cancer

MalaCards organs/tissues related to Lip Cancer:

⁴¹

Eye, Skin, Brain, Bone, Colon, Thyroid, Salivary Gland

Sources

Publications for Lip Cancer

Articles related to Lip Cancer:

(show top 50) (show all 111)

#	Title	Authors	Year
1	Expression of cancer stem cell markers CD44, ALDH1 and p75NTR in actinic cheilitis and lip cancer. ( 29779037 )	CustA^dio M....Trierveiler M.	2018
2	Neglected Under Lip Cancer. ( 29483993 )	Tchernev G...Lozev I	2018
3	Risk of lip cancer after solid organ transplantation in the United States. ( 30074684 )	Laprise C...Engels EA	2018
4	Lip Cancer: Reconsidering the at-risk patients with pathological assessment. ( 30548899 )	Ant A...Bozdogan N	2018
5	AHNS Series - Do you know your guidelines? Lip cancer. ( 28580768 )	Dougherty W....Jameson M.J.	2017
6	Clinicopathological study of lip cancer: a retrospective hospital-based study in Taiwan. ( 28913905 )	Tseng H.W....Shiue Y.L.	2017
7	Changes in the Incidence of Skin and Lip Cancer Between 1978 and 2007. ( 28190452 )	MartA-n GarcA-a E....BuendA-a-Eisman A.	2017
8	Hydrochlorothiazide use is strongly associated with risk of lip cancer. ( 28480532 )		2017
9	Intraoral stents in preventing adverse radiotherapeutic effects in lip cancer patients. ( 28883766 )		2017
10	Stage is a prognostic factor for surgically treated patients with early-stage lip cancer for whom a 'wait and see' policy in terms of neck status has been implemented. ( 28807064 )	Eskiizmir G...Ozyurt BC	2017
11	Two-Piece Extraoral Prosthetic Rehabilitation to a Perineural Invasion Lip Cancer. ( 27517479 )	A9ahan M.H....AteA9 P.	2016
12	Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer. ( 27628318 )	Assao A....Oliveira D.T.	2016
13	Lip cancer: A 16-year retrospective epidemiological study in Eastern part of Turkey. ( 27812062 )	Bozan N....Erten R.	2016
14	Correlation between cell cycle proteins and hMSH2 in actinic cheilitis and lip cancer. ( 26842232 )	Lopes M.L....da Silveira A.8.J.	2016
15	Lip Cancer: A Clinicopathological Study and Treatment Outcomes in a 25-Year Experience. ( 26917204 )		2016
16	Oral cavity and lip cancer: United Kingdom National Multidisciplinary Guidelines. ( 27841120 )		2016
17	High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. ( 26830865 )	Na R...Vajdic CM	2016
18	Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations. ( 26084614 )	Correa G.T....Gomes C.C.	2015
19	Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. ( 25753473 )		2015
20	The pattern of lip cancer occurrence over the 1990-2011 period in public hospitals in Madrid, Spain. ( 26256568 )		2015
21	Oral and lip cancer in solid organ transplant patients--a cohort study from a Swedish Transplant Centre. ( 25497104 )		2015
22	Long-term outcome and subjective quality of life after surgical treatment of lower lip cancer. ( 25261402 )	SchA1ller M....Ettl T.	2014
23	Early diagnosis of lip cancer preceded by a persistent actinic lesion in a kidney transplant patient: a case report. ( 24983181 )	Oliveira F.A....Sousa F.B.	2014
24	Quantification of the Surgical Margin Shrinkage in Lip Cancer: Determining the Relation Between the Surgical and Histopathologic Margins. ( 25329844 )	Egemen O....Akan M.	2014
25	Facial cutaneous metastases of advanced rectal malignancy masquerading as lip cancer. ( 25370567 )		2014
26	Study of MDM2 and SUMO-1 expression in actinic cheilitis and lip cancer. ( 25241153 )		2014
27	Technique for histological control of surgical margins in lip cancer. ( 24611955 )		2014
28	Pulsed dose rate brachytherapy of lip cancer. ( 24143149 )		2013
29	Antihypertensive drugs and lip cancer in non-Hispanic whites. ( 22869299 )	Friedman G.D....Habel L.A.	2012
30	High dose-rate versus low dose-rate brachytherapy for lip cancer. ( 22099044 )	Ghadjar P....Aebersold D.M.	2012
31	Lip cancer: a 10-year retrospective epidemiological study. ( 22493399 )	Maruccia M....Scuderi N.	2012
32	Lip cancer: retrospective analysis of 181 cases. ( 22136191 )		2012
33	Wave technique for treatment of lower lip cancer. ( 22440315 )		2012
34	Sun protection for all: but especially for those receiving certain hypertensive medications: comment on &quot;Antihypertensive drugs and lip cancer in non-Hispanic whites&quot;. ( 22869333 )		2012
35	High-dose-rate interstitial brachytherapy in early stage buccal mucosa and lip cancer: report on 12 consecutive patients and review of the literature. ( 23052164 )		2012
36	Surgical management of lip cancer. ( 21808457 )	Moretti A....Croce A.	2011
37	Lip cancer in renal transplant patients. ( 21112239 )		2011
38	Long term results of PDR brachytherapy for lip cancer. ( 27895671 )	Johansson B...Persliden J	2011
39	Occupational exposure to the sun and risk of skin and lip cancer among male wage earners in Denmark: a population-based case-control study. ( 20383781 )	Kenborg L....Hansen J.	2010
40	Lip cancer: incidence, trends, histology and survival: 1970-2006. ( 20163415 )	Czerninski R....Sgan-Cohen H.D.	2010
41	Lip cancer: a 5-year review in a tertiary referral centre. ( 20129833 )		2010
42	HDR and LDR Brachytherapy in the Treatment of Lip Cancer: the Experience of the Catalan Institute of Oncology. ( 28031737 )	Ayerra AQ...Guedea F	2010
43	Surgical treatment of lip cancer: our experience with 106 cases. ( 19304043 )	Salgarelli A.C....Collini M.	2009
44	Lip cancer in Western Australia, 1982-2006: a 25-year retrospective epidemiological study. ( 19473154 )	Abreu L....Tennant M.	2009
45	Is elective neck dissection in T1-2, N0 patients with lower lip cancer necessary? ( 19325341 )		2009
46	Immunosuppression and other risk factors for lip cancer after kidney transplantation. ( 19190169 )		2009
47	Survival after lip cancer diagnosis. ( 19165039 )		2009
48	Sentinel lymph node biopsy (SLNB) in management of N0 stage T1-T2 lip cancer as a &quot;same day&quot; procedure. ( 17936674 )	Khalil H.H....El-Refaie K.M.	2008
49	Comparison of time trends in lip cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV-VIII. ( 18573854 )	Yako-Suketomo H....Marugame T.	2008
50	Continuous intraarterial infusion chemotherapy for early lip cancer. ( 17207655 )	Wu C.F....Sheen M.C.	2007

Sources

Genes for Lip Cancer

Genes related to Lip Cancer (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SUMO1	Small Ubiquitin-Like Modifier 1	Protein Coding	20.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	MSH2	MutS Homolog 2	Protein Coding	20.33	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	TP53	Tumor Protein P53	Protein Coding	20.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	MDM2	MDM2 Proto-Oncogene	Protein Coding	19.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	LIPT2	Lipoyl(Octanoyl) Transferase 2	Protein Coding	16.75	DISEASES inferred ¹⁵
6	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	16.32	GeneCards inferred via : Publications (show sections)

Sources

Variations for Lip Cancer

Sources

Expression for Lip Cancer

Search GEO for disease gene expression data for Lip Cancer.

Sources

Pathways for Lip Cancer

Pathways related to Lip Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 64)

#	Super pathways	Score	Top Affiliating Genes
1	Gene Expression ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶	13.55	CDKN1A MDM2 MSH2 SUMO1 TP53
2	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.19	CDKN1A MDM2 SUMO1 TP53
3	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	12.77	CDKN1A MDM2 MSH2 TP53
4	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.66	CDKN1A MDM2 MSH2 TP53
5	Pathways in cancer ³⁷	12.62	CDKN1A MDM2 MSH2 TP53
6	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ¹ Apoptosis ³⁷ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁵ Death Receptor Signaling ⁶⁷	12.61	CDKN1A MDM2 TP53
7	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.57	CDKN1A MDM2 TP53
8	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.54	CDKN1A MDM2 TP53
9	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.42	CDKN1A MSH2 TP53
10	SUMOylation ⁶⁶ Show member pathways Processing and activation of SUMO ⁶⁶ SUMO E3 ligases SUMOylate target proteins ⁶⁶ SUMO is conjugated to E1 (UBA2-SAE1) ⁶⁶ SUMO is proteolytically processed ⁶⁶ SUMO is transferred from E1 to E2 (UBE2I, UBC9) ⁶⁶ SUMOylation of chromatin organization proteins ⁶⁶ SUMOylation of DNA damage response and repair proteins ⁶⁶ SUMOylation of transcription factors ⁶⁶	12.41	MDM2 SUMO1 TP53
11	Mitotic G1-G1/S phases ⁶⁶ Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶⁶	12.4	CDKN1A MDM2 TP53
12	Cell Cycle Checkpoints ⁶⁶ Show member pathways G2/M Checkpoints ⁶⁶	12.38	CDKN1A MDM2 SUMO1 TP53
13	MicroRNAs in cancer ³⁷	12.35	CDKN1A MDM2 TP53
14	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.32	CDKN1A MDM2 TP53
15	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.26	CDKN1A MDM2 MSH2 SUMO1 TP53
16	DNA Damage ⁴	12.25	CDKN1A MDM2 MSH2 TP53
17	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.24	CDKN1A MDM2 TP53
18	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.22	CDKN1A MDM2 TP53
19	Cell cycle ¹ ³⁷	12.21	CDKN1A MDM2 TP53
20	Epstein-Barr virus infection ³⁷	12.15	CDKN1A MDM2 TP53
21	Proteoglycans in cancer ³⁷	12.14	CDKN1A MDM2 TP53
22	Viral carcinogenesis ³⁷	12.14	CDKN1A MDM2 TP53
23	Transcriptional misregulation in cancer ³⁷	12.1	CDKN1A MDM2 TP53
24	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.09	CDKN1A MDM2 TP53
25	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.04	CDKN1A MDM2 TP53
26	Colorectal Cancer Metastasis ⁶⁴	12.03	CDKN1A MSH2 TP53
27	Cellular senescence (KEGG) ³⁷	12.01	CDKN1A MDM2 TP53
28	Integrated Breast Cancer Pathway ¹	11.99	MDM2 MSH2 TP53
29	AKT Signaling Pathway ⁶⁷	11.98	CDKN1A MDM2 TP53
30	TGF-beta Signaling Pathway (WikiPathways) ¹	11.9	CDKN1A SUMO1 TP53
31	DNA Damage Response (only ATM dependent) ¹	11.83	CDKN1A MDM2 TP53
32	Glioblastoma Multiforme ⁶⁴	11.81	CDKN1A MDM2 TP53
33	SMAD Signaling Network ⁶⁴	11.79	CDKN1A MDM2 SUMO1 TP53
34	Senescence and Autophagy in Cancer ¹	11.77	CDKN1A MDM2 TP53
35	Direct p53 effectors ¹	11.74	CDKN1A MDM2 MSH2 TP53
36	Androgen receptor signaling pathway ¹	11.69	CDKN1A MDM2 SUMO1
37	Retinoblastoma (RB) in Cancer ¹	11.67	CDKN1A MDM2 TP53
38	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.65	MSH2 TP53
39	ATM Pathway ⁶⁴ Show member pathways ATM Signaling Pathway ¹	11.65	CDKN1A MDM2 TP53
40	Glucocorticoid receptor regulatory network ¹	11.61	CDKN1A MDM2 TP53
41	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.59	MDM2 TP53
42	Bladder cancer ³⁷ ¹	11.53	CDKN1A MDM2 TP53
43	p53 pathway ¹	11.49	MDM2 TP53
44	Regulation of retinoblastoma protein ¹	11.47	CDKN1A MDM2
45	Copper homeostasis ¹	11.45	MDM2 TP53
46	HIF1Alpha Pathway ⁶⁴	11.45	MDM2 TP53
47	Hepatitis C and Hepatocellular Carcinoma ¹	11.42	CDKN1A TP53
48	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.42	CDKN1A TP53
49	miRNAs involved in DNA damage response ¹	11.41	CDKN1A TP53
50	Transcription_P53 signaling pathway ²²	11.4	CDKN1A MDM2 SUMO1 TP53

Sources

GO Terms for Lip Cancer

Cellular components related to Lip Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.55	CDKN1A MDM2 MSH2 SUMO1 TP53
2	nucleolus	GO:0005730	9.26	CDKN1A MDM2 SUMO1 TP53
3	nuclear body	GO:0016604	8.92	CDKN1A MDM2 SUMO1 TP53

Biological processes related to Lip Cancer according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	cellular response to DNA damage stimulus	GO:0006974	9.77	CDKN1A MSH2 TP53
2	viral process	GO:0016032	9.73	MDM2 SUMO1 TP53
3	regulation of signal transduction by p53 class mediator	GO:1901796	9.6	MDM2 TP53
4	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	GO:0032436	9.58	MDM2 SUMO1
5	Ras protein signal transduction	GO:0007265	9.58	CDKN1A TP53
6	cellular response to heat	GO:0034605	9.57	CDKN1A SUMO1
7	protein sumoylation	GO:0016925	9.55	MDM2 SUMO1
8	cellular response to ionizing radiation	GO:0071479	9.54	CDKN1A TP53
9	intrinsic apoptotic signaling pathway	GO:0097193	9.52	CDKN1A TP53
10	response to antibiotic	GO:0046677	9.51	MDM2 TP53
11	positive regulation of reactive oxygen species metabolic process	GO:2000379	9.49	CDKN1A TP53
12	cellular response to gamma radiation	GO:0071480	9.48	MDM2 TP53
13	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	9.46	MSH2 TP53
14	response to X-ray	GO:0010165	9.43	CDKN1A MSH2
15	cell cycle arrest	GO:0007050	9.43	CDKN1A MSH2 TP53
16	positive regulation of protein export from nucleus	GO:0046827	9.4	MDM2 TP53
17	determination of adult lifespan	GO:0008340	9.37	MSH2 TP53
18	replicative senescence	GO:0090399	9.32	CDKN1A TP53
19	signal transduction by p53 class mediator	GO:0072331	9.16	CDKN1A TP53
20	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.13	CDKN1A MDM2 TP53
21	cellular response to actinomycin D	GO:0072717	8.62	MDM2 TP53

Molecular functions related to Lip Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.54	CDKN1A MSH2 TP53
2	p53 binding	GO:0002039	9.32	MDM2 TP53
3	disordered domain specific binding	GO:0097718	9.26	MDM2 TP53
4	enzyme binding	GO:0019899	9.26	MDM2 MSH2 SUMO1 TP53
5	SUMO transferase activity	GO:0019789	9.16	MDM2 SUMO1
6	ubiquitin protein ligase binding	GO:0031625	8.92	CDKN1A MDM2 SUMO1 TP53

Sources

Sources for Lip Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia